Abstract
Sorafenib (Nexavar(A (R))) is currently the only systemic agent approved for use in hepatocellular carcinoma (HCC). Its approval was based on the resu......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
